WASHINGTON — Pfizer Inc on Tuesday began submitting data to federal regulators as part of the process to win U.S. approval of its COVID-19 vaccine for children under age 5, Bloomberg reported.
"It’ll be a rolling submission that may ultimately include data to support giving a third dose," Bloomberg reporter Josh Wingrove tweeted.
Newsletter sign-up: Get The COVID-19 Brief sent to your inbox
Pfizer and partner BioNTech’s vaccine is already approved for children in the United States age 5 and older.
RELATED IMAGESview larger image
A health worker prepares a dose of the Pfizer coronavirus vaccine for a student at a school in Karachi, Pakistan, Jan. 24, 2022. (AP Photo/Fareed Khan)
